Thursday , September 20 2018
Home / Letter From The Editor / Letter from the Editor #651

Letter from the Editor #651

Nov 9, 2012

This week week the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended that degludec, Novo’s new long acting insulin, be approved for use in the United States. There was a lot of the usual fuss about CV studies that seems to go along with with every new diabetes drug, but this time the panel agreed on a post-marketing cardiovascular outcomes trial for the product’s two formulations, and that means the drug will get to market a lot sooner. Now that it is on the way the real questions are how much will it cost, and will insurers pony up the extra money for the medication?

If you have an interest in learning more about this new class of insulins then be sure and look for our Homerun Slides in next week’s Diabetes Clinical Mastery Series newsletter.

While you are checking out the slides you may also want to "google" yourself and see what has been posted about you and your practice as one out of every five patients uses online search engine information to choose a primary care physician. Check out this week’s Item #6, Patients Searching Internet for Info on Their Docs, and find out if you need to put more effort into beefing up your online presence.


Topics: dLife profiles Tampa Bay Rays outfielder Sam Fuld and his camp for kids with diabetes. Also, a return to the supermarket for great ways to satisfy your sweet tooth without spiking your blood sugar. Sundays on CNBC at 7 PM ET, 6 PM CT, and 4 PM PT. Catch up on

The TCOYD Continuing Medical Education Program offers a unique opportunity to bridge patient and professional education, demonstrating the link between clinical lessons in the classroom to the real life patient experience. Find out more here.
Please answer this week’s poll: Are you happy with the election results?
We can make a difference!
Check out this week’s Test Your Knowledge question.

Dave Joffe, Editor-in-chief